Swiss National Bank
FULC icon

Swiss National Bank’s Fulcrum Therapeutics FULC Stock Holding History

Swiss National Bank’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-86,500
Closed -$247K – 2626
2023
Q1 		$247K Sell
86,500
-3,100
-3% -$27.8K ﹤0.01% 2628
2022
Q4 		$652K Hold
89,600
– – ﹤0.01% 2510
2022
Q3 		$725K Buy
89,600
+27,200
+44% +$195K ﹤0.01% 2457
2022
Q2 		$306K Hold
62,400
– – ﹤0.01% 2709
2022
Q1 		$1.48M Buy
62,400
+6,200
+11% +$87.8K ﹤0.01% 2208
2021
Q4 		$994K Buy
+56,200
New +$1.11M ﹤0.01% 2479

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Swiss National Bank's FULC Position: Q2 2023 in Review

Swiss National Bank sold out of Fulcrum Therapeutics (FULC) in Q2 2023, closing a stake of 86,500 shares — an estimated $247K sold.

Swiss National Bank first reported a position in FULC in Q4 2021 and held it in 6 quarters. The position peaked at $1.48M in Q1 2022. 88 funds tracked by Wall St. Rank hold FULC as of Q2 2023.

  • Swiss National Bank reported no remaining Fulcrum Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Swiss National Bank sold 86,500 Fulcrum Therapeutics shares in Q2 2023, an estimated $247K.
  • Swiss National Bank first reported a position in Fulcrum Therapeutics in Q4 2021 and held it in 6 quarters.
  • Swiss National Bank's Fulcrum Therapeutics position peaked at $1.48M in Q1 2022.
  • 88 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2023.

Based on Swiss National Bank's 13F filing for Q2 2023, filed 9 Aug 2023.